Phio Pharmaceuticals (NASDAQ: PHIO) to present and advance Phase 1b trial

Rhea-AI Filing Summary

Phio Pharmaceuticals Corp. reported that it will present at the H.C. Wainwright 27th Annual Global Investment Conference, which is scheduled for September 8-10, 2025. The company also noted that patients are now being treated in the 5th cohort of its ongoing Phase 1b clinical trial for skin cancer, indicating continued progression of this early-stage study.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001533040 0001533040 2025-09-03 2025-09-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): September 3, 2025

PHIO PHARMACEUTICALS CORP.

(Exact name of registrant as specified in its charter)

Delaware		001-36304		45-3215903
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

411 Swedeland Road, Suite 23-1080
King of Prussia, PA	19406
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (508) 767-3861

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class:		Trading Symbol(s):		Name of each exchange on which registered:
Common Stock, par value $0.0001 per share		PHIO		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On September 3, 2025, Phio Pharmaceuticals Corp. (“Phio”) issued a press release announcing that it is a presenting company at the H.C. Wainwright 27^th Annual Global Investment Conference to be held September 8-10, 2025. Phio also announced in the press release that patients are now being treated in the 5^th cohort of its ongoing Phase 1b clinical trial for skin cancer.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Number		Description
99.1		Press Release, dated September 3, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 3, 2025	PHIO PHARMACEUTICALS CORP.
	By:	/s/ Robert J. Bitterman
	Name: Title:	Robert J. Bitterman President & Chief Executive Officer

3

FAQ

What did Phio Pharmaceuticals (PHIO) disclose in this 8-K filing?

Phio Pharmaceuticals disclosed that it will be a presenting company at the H.C. Wainwright 27th Annual Global Investment Conference and that patients are now being treated in the 5th cohort of its ongoing Phase 1b clinical trial for skin cancer.

What clinical update did Phio Pharmaceuticals (PHIO) provide?

Phio Pharmaceuticals reported that patients are now being treated in the 5th cohort of its ongoing Phase 1b clinical trial for skin cancer, showing the trial is proceeding through its planned dose or treatment cohorts.

Which investor conference will Phio Pharmaceuticals (PHIO) attend?

Phio Pharmaceuticals announced it is a presenting company at the H.C. Wainwright 27th Annual Global Investment Conference, which will be held September 8-10, 2025.

Does this 8-K from Phio Pharmaceuticals (PHIO) include financial results?

No, this 8-K focuses on other events, specifically an investor conference appearance and a clinical trial cohort update, and does not provide financial results.

Who signed the Phio Pharmaceuticals (PHIO) 8-K report?

The report was signed on behalf of Phio Pharmaceuticals Corp. by Robert J. Bitterman, President and Chief Executive Officer.